TYRA
TYRA clinical trials: Tyra Biosciences, Inc.
Every trial on ClinicalTrials.gov where Tyra Biosciences, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 7
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
TYRA on the catalyst calendar · TYRA registry changes
- Primary completion Jan 2030Sponsor estimatePhase 2NCT06842355A Study of TYRA-300 in Children With Achondroplasia: BEACH301Tyra Biosciences, Inc · AchondroplasiaRecruitingTYRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2030Sponsor estimatePhase 2NCT07265947Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaTyra Biosciences, Inc · Low Grade Upper Tract Urothelial CarcinomaRecruitingTYRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2028Sponsor estimatePhase 2NCT06995677Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder CancerTyra Biosciences, Inc · Low-grade NMIBCRecruitingTYRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 1NCT06160752Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene AlterationsTyra Biosciences, Inc · Locally Advanced CholangiocarcinomaActive, not recruitingTYRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 1NCT06915753Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating...Tyra Biosciences, Inc · Metastatic Hepatocellular CarcinomaRecruitingTYRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2026Sponsor estimatePhase 1/Phase 2NCT05544552Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene AlterationsTyra Biosciences, Inc · Locally Advanced Urothelial CarcinomaActive, not recruitingTYRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2025Sponsor estimatePhase 1NCT06006702A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult ParticipantsTyra Biosciences, Inc · HealthyActive, not recruitingTYRALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner